• Safety and feasibility
  
• Graft-versus-host disease rate
  

• Pattern of post-transplantation CD4+ and CD8+ T-cell production of Th1- and Th2-type cytokines
  
• Kinetics of alloengraftment
  
• Incidence of opportunistic infection
  
• Incidence of malignant disease in complete remission
  
• Reactivity of T cells collected after transplantation
  
• Pattern of post-transplantation CD14+ monocyte production of inflammatory cytokines, interleukin-1-alpha, and tumor necrosis factor alpha
  

DISEASE CHARACTERISTICS:

• Histological diagnosis of 1 of the following hematologic malignancies, myelodysplasia, or myeloproliferative disorders:

  • Chronic lymphocytic leukemia

    • Relapsed after fludarabine
    • Non-complete remission (CR) after salvage regimen

  • Hodgkin's or non-Hodgkin's lymphoma (all types, including mantle cell lymphoma)

    • Primary treatment failure
    • Relapsed after autologous stem cell transplantation (SCT)
    • Non-CR after salvage regimen

  • Multiple myeloma

    • Primary treatment failure
    • Relapsed after autologous SCT
    • Non-CR after salvage regimen

  • Acute myeloid leukemia

    • In first CR (CR1) and at high risk [excludes t(8;21), t(15;17), or inv(16)]
    • In second CR (CR2) or greater

  • Acute lymphoblastic leukemia

    • In CR1 and at high risk [t(9;22) or bcr-abl+; t(4;11), 1(1;19), t(8;14)]
    • In CR2 or greater

  • Myelodysplastic syndromes

    • Refractory anemia with excess blasts (RAEB)
    • RAEB in transformation (requires bone marrow and blood blasts of less than 10% after induction chemotherapy)

  • Myeloproliferative disorders*

    • Idiopathic myelofibrosis
    • Polycythemia vera
    • Essential thrombocythemia
    • Chronic myelomonocytic leukemia NOTE: *Patients must be end-stage, primarily defined as disease severity refractory to splenectomy

  • Chronic myelogenous leukemia

    • Chronic phase refractory to imatinib mesylate
    • Accelerated phase
• Acute leukemia must be in hematologic remission (less than 5% of blood or marrow blasts)
• Must have a first-degree relative donor matched at 6/6 HLA antigens (A, B, and DR)
• No active CNS involvement by malignancy

PATIENT CHARACTERISTICS:

Age

• 18 to 75

Performance status

• ECOG 0-1

Life expectancy

• At least 3 months

Hematopoietic

• Not specified

Hepatic

• ALT and AST no greater than 2.5 times upper limit of normal*
• Bilirubin less than 2.5 mg/dL* NOTE: *Values above these levels may be accepted, at the discretion of the principal investigator or study chairman, if the elevations are due to liver involvement

Renal

• Creatinine no greater than 1.5 mg/dL
• Creatinine clearance at least 50 mL/min

Cardiovascular

• LVEF greater than 45% by 2-dimensional ECHO or MUGA

Pulmonary

• DLCO greater than 50% of expected

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for at least 1 year after study participation
• HIV negative
• No active infection that is not responding to antimicrobial therapy
• No psychiatric illness that would preclude study compliance or informed consent

PRIOR CONCURRENT THERAPY:

Biologic therapy

• See Disease Characteristics

Chemotherapy

• See Disease Characteristics

Endocrine therapy

• No concurrent steroids as antiemetics during chemotherapy
• No concurrent steroids during transplantation

Surgery

• See Disease Characteristics

Other

• At least 2 weeks since prior therapy and recovered